Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 15:4:385.
doi: 10.3389/fonc.2014.00385. eCollection 2014.

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Margaret K Callahan  1 , Michael A Postow  1 , Jedd D Wolchok  2
Affiliations
Review

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Margaret K Callahan et al. Front Oncol. .

Abstract

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.

Keywords: CLTA-4; PD-1; immunotherapy; ipilimumab; nivolumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1:405–13.10.1016/1074-7613(94)90071-X - DOI - PubMed
    1. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity (1994) 1:501–8.10.1016/1074-7613(94)90092-2 - DOI - PubMed
    1. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 182:459–65.10.1084/jem.182.2.459 - DOI - PMC - PubMed
    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271:1734–6.10.1126/science.271.5256.1734 - DOI - PubMed
    1. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 13:5. Available frpm: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559193/ - PMC - PubMed